Vial Health | Ablon Skin Institute & Research Center
Status
Conditions
Treatments
About
To evaluate repigmentation and quality of life after treatment of stable vitiligo lesions using the RECELL Device.
Full description
Prospective, multicenter single-arm pre-/post interventional study to evaluate the clinical performance of RECELL for repigmentation of stable depigmented lesions.Skin cell suspension prepared using the RECELL System will be applied to a prepared treatment area, followed by at-home NB-UVB phototherapy.
Repigmentation of treatment areas will be determined via centralized image interpretation by an expert dermatological panel (i.e., Central Review Committee, CRC).
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Focal, segmental, or generalized (i.e., nonsegmental) stable vitiligo, defined as no new depigmented areas nor any depigmented areas that have expanded in size within the preceding 12 months.
The patient is a candidate for surgical intervention of a depigmented area, defined as a patient who has not satisfactorily responded to either:
The patient has a depigmented area available for treatment that is:
The patient is 18 years of age or older.
The patient agrees to remain on any current use of immunosuppressive therapy for the duration of his/her participation in the study (52 weeks).
The patient is willing and able to comply with post-treatment at-home phototherapy and all follow-up study visits.
The patient agrees to abstain from any other treatment of the study area for the duration of his/her participation in the study (52 weeks).
The patient agrees to abstain from enrollment in any other interventional clinical trial for the duration of his/her participation in the study (52 weeks).
In the opinion of the investigator, the patient must be able to:
Exclusion criteria
The patient is unable to undergo treatment area preparation.
Patients who received RECELL treatment for vitiligo in Protocol No. CTP008 or CTP009.
Patients with:
Patients with recent history (within previous 12 months) of:
Patients with a history of keloid formation.
The patient has other concurrent conditions that in the opinion of the investigator may compromise patient safety or study objectives.
Current use of medications (e.g., anticoagulants such as heparin or warfarin) that in the investigator's opinion may compromise patient safety or trial objectives.
The patient has a known hypersensitivity to trypsin, compound sodium lactate for irrigation solution (Hartmann's solution), povidone-iodine, chlorhexidine, and/or lidocaine-containing anesthetics -
Primary purpose
Allocation
Interventional model
Masking
109 participants in 1 patient group
Loading...
Central trial contact
Elizabeth Kirshner
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal